Admissions of adolescents at Vogur have fallen by over 50% since 2002

Efst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkin

Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents

Publisher's version (útgefin grein)A nationwide programme for the treatment of all patients infected with hepatitis C virus (HCV) was launched in Iceland in January 2016. By providing universal access to direct‐acting antiviral agents to the entire patient population, the two key aims of the project were to (i) offer a cure to patients and thus reduce the long‐term sequelae of chronic hepatitis C, and (ii) to reduce domestic incidence of HCV in the population by 80% prior to the WHO goal of HCV elimination by the year 2030. An important part of the programme is that vast majority of cases will be treated within 36 months from the launch of the project, during 2016–2018. Emphasis is placed on early case finding and treatment of patients at high risk for transmitting HCV, that is people who inject drugs (PWID), as well as patients with advanced liver disease. In addition to treatment scale‐up, the project also entails intensification of harm reduction efforts, improved access to diagnostic tests, as well as educational campaigns to curtail spread, facilitate early detection and improve linkage to care. With these efforts, Iceland is anticipated to achieve the WHO hepatitis C elimination goals well before 2030. This article describes the background and organization of this project. Clinical trial number: NCT02647879.Sigurdur Olafsson: Speaker's fee from Merck. Magnus Gottfredsson: Speaker's fee from Astellas and Gilead. MH and the Burnet Institute receive investigator‐initiated research funding from Gilead Sciences, AbbVie and BMS.Peer Reviewe

Greining lifrarbólguveiru B: faraldur meðal fíkniefnaneytenda

Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/OpenDuring the period of three years from April 1988 to April 1991, there were 85 cases of hepatitis B infection identified at the Department of Medical Virology, University of Iceland. The great majority of these patients were from the age of 15-40 years and had a history of intravenous drug use. To study the prevalence of previous hepatitis B infection the anti HBC marker was measured in a group of 1100 individuals of various age. None within 15 years of age tested positive to the anti HBC marker but its prevalence rose with age to 6.5% at the age of 64 and higher. The prevalence of the anti HBt marker was also studied among individuals with a recent history of intravenous drug use. Of 34 individuals 11 (32%) had the anti HBC marker. It is clear that hepatitis B infection has spread rapidly among intravenous drug users in Iceland.Á Rannsóknastofu Háskólans í veirufræði tók áhætturannsóknadeild til starfa í apríl 1988. Fyrstu þrjú starfsár deildarinnar greindust 85 ný tilfelli lifrarbólguveiru B sýkingar. Flestir hinna nýsýktu voru á aldrinum 15-40 ára og voru fíkniefnaneytendur sem höfðu sprautað sig í æð og notað sameiginlegar sprautur. Til að kanna algengi fyrri lifrarbólguveiru B sýkinga voru kjarnamótefni mæld í úrtaki sýna frá 1100 einstaklingum á ýmsum aldri. Engir innan 15 ára aldurs höfðu kjarnamótefni en algengi þeirra fór síðan vaxandi með hækkandi aldri og meðal 64 ára og eldri reyndist algengið 6,5%. Einnig var athugað algengi fyrri sýkinga hjá hópi einstaklinga sem hafði sögu um nýlega fíkniefnaneyslu í æð. Af 34 einstaklingum reyndust 11 (32%) með kjarnamótefni gegn lifrarbólguveiru B. Er ljóst að lifrarbóiguveiru B sýking hefur breiðst mjög hratt út meðal sprautufíkla hérlendis

Greining lifrarbólguveiru B: faraldur meðal fíkniefnaneytenda

Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/OpenDuring the period of three years from April 1988 to April 1991, there were 85 cases of hepatitis B infection identified at the Department of Medical Virology, University of Iceland. The great majority of these patients were from the age of 15-40 years and had a history of intravenous drug use. To study the prevalence of previous hepatitis B infection the anti HBC marker was measured in a group of 1100 individuals of various age. None within 15 years of age tested positive to the anti HBC marker but its prevalence rose with age to 6.5% at the age of 64 and higher. The prevalence of the anti HBt marker was also studied among individuals with a recent history of intravenous drug use. Of 34 individuals 11 (32%) had the anti HBC marker. It is clear that hepatitis B infection has spread rapidly among intravenous drug users in Iceland.Á Rannsóknastofu Háskólans í veirufræði tók áhætturannsóknadeild til starfa í apríl 1988. Fyrstu þrjú starfsár deildarinnar greindust 85 ný tilfelli lifrarbólguveiru B sýkingar. Flestir hinna nýsýktu voru á aldrinum 15-40 ára og voru fíkniefnaneytendur sem höfðu sprautað sig í æð og notað sameiginlegar sprautur. Til að kanna algengi fyrri lifrarbólguveiru B sýkinga voru kjarnamótefni mæld í úrtaki sýna frá 1100 einstaklingum á ýmsum aldri. Engir innan 15 ára aldurs höfðu kjarnamótefni en algengi þeirra fór síðan vaxandi með hækkandi aldri og meðal 64 ára og eldri reyndist algengið 6,5%. Einnig var athugað algengi fyrri sýkinga hjá hópi einstaklinga sem hafði sögu um nýlega fíkniefnaneyslu í æð. Af 34 einstaklingum reyndust 11 (32%) með kjarnamótefni gegn lifrarbólguveiru B. Er ljóst að lifrarbóiguveiru B sýking hefur breiðst mjög hratt út meðal sprautufíkla hérlendis